Cutting Edge: identification of neutrophil PGLYRP1 as a ligand for TREM-1

  • J Immunol. 2015 Feb 15;194(4):1417-21. doi: 10.4049/jimmunol.1402303.
Christine B Read  1 ,  Joseph L Kuijper  2 ,  Siv A Hjorth  3 ,  Mark D Heipel  2 ,  Xiaoting Tang  2 ,  Andrew J Fleetwood  1 ,  Jeffrey L Dantzler  2 ,  Susanne N Grell  1 ,  Jesper Kastrup  1 ,  Camilla Wang  2 ,  Cameron S Brandt  2 ,  Anker J Hansen  1 ,  Nicolai R Wagtmann  1 ,  Wenfeng Xu  2 ,  Vibeke W Stennicke  4
Affiliations
  • 1. Novo Nordisk A/S, DK-2760 Måløv, Denmark; and.
  • 2. Novo Nordisk Research Center, Seattle, WA 98109.
  • 3. Novo Nordisk A/S, DK-2760 Måløv, Denmark; and Novo Nordisk Research Center, Seattle, WA 98109.
  • 4. Novo Nordisk A/S, DK-2760 Måløv, Denmark; and [email protected].
Abstract

Triggering receptor expressed on myeloid cells (TREM)-1 is an Orphan Receptor implicated in innate immune activation. Inhibition of TREM-1 reduces Sepsis in mouse models, suggesting a role for it in immune responses triggered by bacteria. However, the absence of an identified ligand has hampered a full understanding of TREM-1 function. We identified complexes between peptidoglycan recognition protein 1 (PGLYRP1) and bacterially derived peptidoglycan that constitute a potent ligand capable of binding TREM-1 and inducing known TREM-1 functions. Interestingly, multimerization of PGLYRP1 bypassed the need for peptidoglycan in TREM-1 activation, demonstrating that the PGLYRP1/TREM-1 axis can be activated in the absence of Bacterial products. The role for PGLYRP1 as a TREM-1 activator provides a new mechanism by which bacteria can trigger myeloid cells, linking two known, but previously unrelated, pathways in innate immunity.